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1.71) or re-admission (HR: 0.89, 95% CI: 0.78-1.02). CONCLUSIONS: The higher risk 
of severe hypoglycemic events and re-admission associated with non-PI-
concordant OAD treatment after being discharged among hospitalized T2DM 
patients with moderate to severe CKD suggests prescribing patterns that 
consider renal impairment may be important from both clinical and economic 
perspectives.  
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OBJECTIVES: To assess the rate of non-concordant use of oral anti-diabetic drugs 
(OAD) according to National Kidney Foundation (NKF) guidelines and drug 
package inserts (PI) among nursing home (NH) residents with diabetes and 
moderate to severe chronic kidney disease (CKD). METHODS: Long-term care 
administrative database with medical and pharmacy claims information was 
analyzed. Residents with diabetes and moderate to severe CKD who remained in 
NHs for at least 90 consecutive days between 2008 and 2011 were selected. 
Residents with moderate to severe CKD was identifed if they had at least one 
glomerular filtration rate <60 ml/min/1.73m2in the 1 year prior to or during the 
90-day period. Concordance was analyzed among residents that filled at least 1 
prescription for OAD during the first 90-day continuous stay. If at least 1 of the 
OADs prescribed was not concordant to NKF or PIs, then that resident was 
classified as non-concordant. RESULTS: Of the 730 diabetic residents with 
diabetes and stage 3-5 CKD, 186 residents used the OADs included in the NKF 
guidelines during their 90-day stay in a NH. Of the 186 residents, 135 (72.6%) 
received the OADs in accordance with NKF guidelines, and 77 (41.4%) received 
the medications in accordance with their respective PIs. There was no significant 
difference in the age, gender, and educational status and NH facility location 
distribution among NKF and PIs concordant and non-concordant groups. 
However, residents in NKF concordant group were more likely to be Hispanic 
(32.6 vs. 13.7%, p<0.05) compared to NKF non-concordant group. CONCLUSIONS: 
The findings suggest that significant proportion of the OAD-treated residents 
with moderate to severe CKD, received at least one OAD prescription that was 
not concordant to NKF guidelines or PIs. Efforts should be made to more closely 
monitor OAD treatments of NH residents  
 
PDB104  
ADHERENCE TO ADA HBA1C TESTING FREQUENCY AND ANTIDIABETIC 
THERAPY GUIDELINES IMPROVES PATIENT OUTCOMES  
Lian J, Liang Y 
Novo Nordisk Inc., Princeton, NJ, USA  
OBJECTIVES: The aim of this retrospective study is to evaluate the adherence of 
type 2 diabetes (T2DM) patients starting drug treatment to the ADA guidelines on 
HbA1Ctesting and treatment modification and determine its impact on treatment 
outcomes. METHODS: Data was obtained from a large health care plan claims 
database between July-2008 to December-2011. Eligible patients were aged ≥18 
years with ≥2 T2DM diagnoses (ICD-9CM codes 250.x0, 250.x2), and were drug-
naïve for ≥6 months before the first antidiabetic drug (termed “index treatment”) 
was required. Patient adherence to the HbA1C testing guideline was defined as an 
initial HbA1C test within 105 days of the index treatment and subsequent tests 
within 105 or 195 days of the previous test depending on the result (≥7 or <7%, 
respectively). Adherence to the drug modification guideline was defined as a 
change in treatment within 45 days of HbA1C ≥7%. Patient outcome after one year 
was evaluated using the HbA1Cvalues closest to 365 days after index treatment. 
RESULTS: Of the 14,164 patients who met the study criteria, 4,419(31.20%) met 
the testing criteria for drug modification (HbA1C ≥7%). Of these patients, 
546(12.36%) met the recommended testing frequency, 934(21.14%) adhered to the 
drug modification guidelines, and 117(2.65%) met both guidelines. The odds ratio 
of a patient achieving the HbA1C target (<7%) who adhered to the testing 
guideline was 4.66 compared with a patient who did not meet the testing 
guideline. Furthermore, the odds ratio of a patient in this population achieving 
the HbA1C target was 4.95 when both guidelines were met, as compared with a 
patient who met neither guideline. CONCLUSIONS: Adherence to ADA guidelines 
on HbA1C testing frequency and therapy modification correlated with improved 
outcomes one year after initial drug treatment.  
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OBJECTIVES: To evaluate the relationship between self-monitoring of blood 
glucose (SMBG) test strip utilization and medication intensification in Type 2 
diabetes mellitus (T2DM). METHODS: A retrospective study of Marketscan data 
examined patients with T2DM with ≥2 prescription claims or a 90-day supply of 
at least one non-insulin antihyperglycemic (AH) agent during a 4-month baseline 
period between July 1, 2006 to December, 31, 2009. The first claim for an AH was 
the index date. Patients were classified by number and dosage of AH agents, and 
by their utilization of SMBG test strips during the baseline period. Utilization of 
AH agents and insulin was assessed during follow-up between months 6-12 post-
index. Medication intensification included an increase between baseline and 
follow-up in the number of AH classes used, an increase in dose, or the addition 
of insulin. An analysis of medication intensification from baseline to follow-up 
between users and non-users of SMBG test strips at baseline was conducted 
using chi-square analysis. RESULTS: Among 824,461 patients selected, 482,854 
used one, 258,477 used two, and 83,130 used three AH agents at baseline. SMBG 
test strip use was observed in 28.3% of the entire population, with 17.0% using >4 
test strips weekly. The following treatment changes occurred from baseline to 
follow-up: no change 67.9%, a decrease in AH classes 13.0%, an increase in AH 
classes 15.4%, initiating insulin 2.5%, and increasing dose 6.8%. The utilization of 
SMBG test strips at baseline in patients with no change or a decrease in 
medication intensification during follow-up was 28.0%, which was significantly 
different compared to SMBG use in patients with an increase in AH classes 
(29.1%), patients initiating insulin (32.8%), and in patients increasing dose (30.6%) 
(all P<0.001). CONCLUSIONS: The use of SMBG test strips is associated with 
medication intensification among users of AH therapy in T2DM.  
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OBJECTIVES: Testosterone is mainly used as androgen replacement therapy. The 
purpose of this study was to describe utilization trends of various testosterone 
formulations in a real life setting, using the RAMQ database. METHODS: Male 
patients covered by the Quebec provincial drug reimbursement program (RAMQ) 
who had used at least one formulation of testosterone in the period from June 1, 
2003 to March 31, 2011 were selected. Characteristics of the treatments were 
analyzed, including switches from one formulation to another. A 1:1 control 
group matched for age of patients not using any formulation of testosterone was 
created and incidence of co-morbidities in patients in the study group was 
compared to the control group. RESULTS: Among a random sample of 125,000 
patients covered by the drug plan, 723 males used at least one formulation of 
testosterone (0.57%). The average age was 57.2 years (SD=14.4). A total of 7 
different formulations of testosterone were used by these patients. The most 
frequent formulations used during the study period were Andriol® (48.4%) and 
Androgel® (41.4%). Testosterone formulations were mainly prescribed by GPs 
(73%), endocrinologists (11.9%) and urologists (7.5%). About 32% of patients used 
more than one formulation during the study period. Among patients who 
switched from one formulation to another, switching to Androgel was the most 
frequent trend. Average treatment persistence varied from 147 days with 
Testim® to 674 days with Androgel. Prevalence of many co-morbidities was 
significantly higher amongst these patients compared to the control group. Co-
morbidities included mental disorders (63.2%), hyperlipidemia (63.8%), 
hypertension (51.2%), articulation pain (32.1%) back pain (31.4%), HIV (6.2%) and 
migraine (6.6%). CONCLUSIONS: Patients on androgen replacement therapy have 
significantly more co-morbidities than controls. A significant proportion of 
patients will switch to a different formulation of testosterone over time, 
Androgel being the most frequent choice.  
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OBJECTIVES: Systemically administered mycophenolate mofetil (MMF) has a 
beneficial effect in psoriasis patients. The purpose of the current study was to 
investigate the efficacy and safety of intralesional MMF in ordinary psoriasis 
vulgaris and to find out the best regimen of treatment. METHODS: In hundred 
plaque psoriasis patients, response to different concentrations (3.125, 6.25, 12.5 
and 25 mg/ml) of MMF have been objectively evaluated and compared to control 
(5% dextrose). Patients were divided into two groups, group (A): patients who 
were injected once every two weeks for six weeks and group (B): patients who 
were injected once every week for six weeks. Patients were followed up 
clinically, histopathologically, and immunohisto-chemically for CD3. RESULTS: 
Maximum response to MMF was achieved 8 weeks after initiation of therapy. 
There was significant reduction of erythema, thickness, scaliness (P≤0.01) but not 
surface area (P=0.152) compared to control. Histopathologically, there was 
significant reduction in scores of parakeratosis, acanthosis, dilatation of 
papillary vessels and density of dermal mononuclear infiltrate. 
Immunohistochemical semi-quantitative analysis revealed variable, but in 
general, obvious degree of reduction in the density of CD3+ cellular infiltrate (i.e. 
T-cells) at the eighth visit compared to the first visit in all specimens examined. 
No significant difference could be seen in the efficacy of different concentrations 
with different regimens. No systemic or local adverse effects were noted  
apart from mild and transient burning sensation especially with higher 
concentrations. CONCLUSIONS: Intralesional MMF could be adopted as a  
safe and effective adjunctive line of treatment especially in localized plaque 
psoriasis.  
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